Navigation Links
ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System
Date:11/5/2009

EDINA, Minn., Nov. 5 /PRNewswire/ -- ARKRAY, Inc., the world's 5th largest manufacturer of diabetes self-monitoring systems, today announced that it has received 510(k) clearance from the US Food and Drug Administration for its new GLUCOCARD Vital blood glucose monitoring system.

The new meter and strip platform, which ARKRAY will make available for distribution in early December, is expected to be a significant complement to the existing GLUCOCARD line of products, and will be ideal for the home medical equipment (HME), durable medical equipment (DME), mail order and managed care markets.

"We're very excited about the latest addition to our GLUCOCARD brand," said Jonathan Chapman, President of ARKRAY, USA. "The Vital meets all of ARKRAY's rigorous design and performance standards. And we can offer it at a price point that will make it an ideal solution for our customers to use in competitive bidding."

The new GLUCOCARD Vital meter and strip platform is highly accurate, auto-coded, requires only 0.5 microliter of blood, holds 250 dowloadable tests in its memory and has a glucose oxydase (GO) strip chemistry that is not affected by interferences that cause testing errors in other common test strips.

The Vital, along with all GLUCOCARD brands, are backed by ARKRAY's unique YouChoose((TM)) wellness program, a comprehensive education and support system that includes printed tools, videos, recipes and an integrated website designed to help patients manage their diabetes.

About ARKRAY USA

ARKRAY manufactures and distributes high-quality, cost-effective products that are simple, convenient, and easy-to-use, including blood glucose meters, test strips, safety lancets, and urine chemistry. ARKRAY invests heavily in R&D and has a strong commitment to high-quality products. For patients, this means access to cutting-edge, reliable products without sacrificing quality, and exceptional customer service.

For more information:

www.glucocardusa.com

SOURCE ARKRAY, Inc.


'/>"/>
SOURCE ARKRAY, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Australien, 24. Februar 2017 ITL Limited, ... des Gesundheitsbereiches, ist erfreut, für das zum 31. ... entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine ... zum Wachstum" finden Sie hier . ... nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... , Feb. 23, 2017 ... insights on the various drugs being developed ... covers all the drugs that are in ... Clinical). The pipeline focuses on novel pharmacologic ... antibodies, stem cell therapies, recombinant proteins and ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of ... of Pittsburgh points to eight genes that may explain why susceptibility to one of ... results of a study published today in the journal npj Schizophrenia. , “There ...
(Date:2/24/2017)... ... ... The Smart Machine Age is here, and it’s disrupting everything. Not only could ... in the United States may be taken over by technology in the next five ... steamrolls over colleagues is drawing to a close. Success will belong to those who ...
(Date:2/24/2017)... ... 24, 2017 , ... With millions of Americans and people ... we all are aware of our options and are empowered with strength and ... launch of its newest edition of "Vision and Hearing" in USA Today, that ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal ... Schanssema ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, ... his attempts to overcome them. , Schanssema, initially unsure of the career path he ...
(Date:2/24/2017)... ... 2017 , ... The California State University Institute for Palliative Care ... interested in palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing ... Diego on Sept. 28 and 29, 2017, on the campus of California State University ...
Breaking Medicine News(10 mins):